anti-CD44v7/8 CAR-T in vivo assay
CD44v7/8 is another alternative splicing isoform of CD44 originally discovered as the lymphocyte homing receptor, which exists in a large range of isoforms functioning as a receptor for the glycosaminoglycan hyaluronan via variability in the pattern of glycosylation (both N- and O-linked) and of multiple splice variants. Since CD44v6 participates in a wide variety of bioprocesses such as cell-cell interactions, cell adhesion and migration, it involves in multiple cellular functions like lymphocyte activation, recirculation and homing, hematopoiesis, and especially tumor metastasis. Therefore, CD44v7/8 is regarded as a functional biomarker and therapeutic target for CAR-T cell immunotherapy.
Anti-CD44v7/8 CAR-T Cell Therapy
The studies of preclinical and clinical anti-CD44v7/8 CAR-T cell therapy has not been reported up to now. Therefore, Creative Biolabs helps researchers capture the brighter and prosperous future of anti-CD44v7/8 CAR-T cell therapy.
Animal Models for in vivo Study of anti-CD44v7/8 CAR-T Cell Therapy
Creative Biolabs offers researchers almost all the animal models generated from the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models for a variety of human malignancies.
Add comment
Comments